| Term es nes pval sidak fdr geneset_size leading_edge leading_edge_size |
| Oxidation by cytochrome p450 0.8463624380167725 2.4237435692593747 0.0153614481650476 0.9999075085697088 0.91300502401923 6 O43169,Q16850,Q6UW02 3 |
| Sphingolipid metabolism overview 0.8376175145634056 2.3473419416299195 0.0189078934933495 0.9999893862480052 0.91300502401923 8 Q13510,O95470,Q96G23,Q06136,P27544 5 |
| Sphingolipid metabolism integrated pathway 0.8376175145634056 2.3473419416299195 0.0189078934933495 0.9999893862480052 0.91300502401923 8 Q13510,O95470,Q96G23,Q06136,P27544 5 |
| Cholesterol biosynthesis with skeletal dysplasias 0.8305005941302117 2.3334133799598153 0.0196264597017836 0.9999931616892512 0.91300502401923 7 Q15392,Q16850,O75845,Q15125,Q14739 5 |
| Glycosaminoglycan degradation 0.8237651587981947 2.3221049638218165 0.0202272844714841 0.9999952662567684 0.91300502401923 6 P06865,P08236,P16278,P15586 4 |
| Proteoglycan biosynthesis 0.8794640829041527 2.180295068369225 0.0292355964004475 0.9999999814516264 0.91300502401923 4 Q8TB61,Q8NCH0 2 |
| Mitochondrial complex iv assembly 0.804648474071249 2.1610579519720843 0.0306908631002298 0.999999992459782 0.91300502401923 10 P14406,P13073,Q9Y241,Q9Y2R0 4 |
| Sphingolipid pathway 0.7956989068454338 2.1370088704083883 0.032597270150074 0.999999997685884 0.91300502401923 9 Q13510,P04062,O95470,Q96G23,Q06136 5 |
| Photodynamic therapyinduced nfe2l2 nrf2 survival signaling 0.7803510458128794 2.1235279973569186 0.0337096319554921 0.9999999988396464 0.91300502401923 6 P09601 1 |
| Nad metabolism 0.8620186426908254 2.1072897729063165 0.0350924693148728 0.99999999950862 0.91300502401923 4 P43490 1 |
| Mitochondrial complex iii assembly 0.7811737603021387 2.051348333283549 0.0402330367217609 0.9999999999800714 0.91300502401923 10 Q6DKK2,O14949,P22695 3 |
| Degradation pathway of sphingolipids including diseases 0.7593435116397271 2.0054067759432046 0.0449195779128668 0.9999999999989432 0.91300502401923 7 P17900,P06280,P16278 3 |
| Caloric restriction and aging 0.8299867659322346 1.9718889388795935 0.0486222862761973 0.9999999999998972 0.91300502401923 4 P43490 1 |
| Glycerophospholipid biosynthetic pathway 0.737549648640381 1.8630402246726976 0.0624566071160377 1.0 0.91300502401923 9 Q86UL3,Q9BTU6,O15228,O95674,Q9HCL2,Q8WUK0,O14735,P48651 8 |
| Omega3 omega6 fatty acid synthesis 0.7047556675251372 1.7676594031964143 0.0771178606889482 1.0 0.91300502401923 6 O15254,Q15067 2 |
| Interactions between loxl4 and oxidative stress pathway 0.7795835863354038 1.7555002476210984 0.0791737783399946 1.0 0.91300502401923 4 Q8TAG9,Q16543 2 |
| Kennedy pathway from sphingolipids 0.7351235886481805 1.730611751208647 0.0835210343698373 1.0 0.91300502401923 5 O95470,P48651,Q9UG56,Q9BVG9 4 |
| Nad biosynthetic pathways 0.6879560640630109 1.686954180928523 0.091612162625269 1.0 0.91300502401923 6 P43490 1 |
| Vitamin d metabolism 0.8578835010673883 1.6768629928518028 0.0935692762257625 1.0 0.91300502401923 3 P04062,P38435 2 |
| Metabolism of spingolipids in er and golgi apparatus 0.8557487038731206 1.6683868414764145 0.0952389586972737 1.0 0.91300502401923 3 O95470,Q06136 2 |
| Estrogen receptor pathway 0.8502400489438439 1.6464958304058408 0.0996617178292975 1.0 0.91300502401923 3 Q9HCL2 1 |
| Sphingolipid metabolism in senescence 0.6954074374737559 1.621808628331295 0.1048443303942483 1.0 0.91300502401923 11 O15269,Q13510,P04062,Q96G23,P42345,Q06136,P16278 7 |
| Triacylglyceride synthesis 0.7096877757841219 1.614088039577093 0.1065083312958463 1.0 0.91300502401923 5 Q9HCL2,O15228,Q9NUQ2 3 |
| Ketogenesis and ketolysis 0.6690135859901915 1.5953283277856103 0.1106388341100785 1.0 0.91300502401923 6 O43772,P53985,P23786 3 |
| Neuroinflammation 0.7242401192281885 1.5139374398234624 0.1300417072113102 1.0 0.9321693804212716 4 P00403 1 |
| Acquired partial lipodystrophy barraquersimons syndrome 0.7145292914858877 1.4712243601674688 0.1412304513353381 1.0 0.9321693804212716 4 P20700,O60725 2 |
| Inclusion body myositis 0.8009587450665557 1.449632444687723 0.1471610434257479 1.0 0.9321693804212716 3 P05067 1 |
| Eicosanoid metabolism via lipooxygenases lox 0.6366576876972219 1.437482370769468 0.1505809785212442 1.0 0.9321693804212716 6 P09960,O15254 2 |
| Vitamin a and carotenoid metabolism 0.7775909420467697 1.3558502398120067 0.1751468225694896 1.0 0.9641109499237964 3 Q8WTV0 1 |
| Familial partial lipodystrophy fpld 0.6148631865013221 1.3077456491755173 0.1909595944348971 1.0 0.9709809886520196 7 O75844,P20700,O60725 3 |
| Endothelin pathways 0.6123065142762479 1.2951326002996877 0.1952744905603445 1.0 0.9763724528017226 7 P00403,P42892 2 |
| Glycerolipids and glycerophospholipids 0.5960760772943309 1.2149833685380222 0.2243724347028939 1.0 1.0 7 Q86UL3,Q9BVG9,Q9HCL2,Q9UG56,P48651 5 |
| Striated muscle contraction pathway 0.5808345812184394 1.1625621168138212 0.24500720849927 1.0 1.0 6 P09493,P08670 2 |
| Eicosanoid synthesis 0.9140243902439024 1.1327488685897769 0.2573197292417308 1.0 1.0 2 P09960 1 |
| Type i collagen synthesis in the context of osteogenesis imperfecta 0.5953270328932534 1.1268769166670862 0.259794524236288 1.0 1.0 11 O75718,P13674,O15460,Q32P28 4 |
| Nanomaterial induced apoptosis 0.5933047502680489 1.07309581636464 0.2832281279062139 1.0 1.0 5 O95831 1 |
| Mitochondrial long chain fatty acid betaoxidation 0.5893807503245639 1.0409610632728947 0.2978936195587858 1.0 1.0 14 O43772,Q16836,P23786,Q9BY49 4 |
| Ferroptosis 0.6093255120841252 1.020418001405576 0.3075302600283134 1.0 1.0 22 P09601,P02786,Q9NZ45,Q9UKU0,P45880,Q9Y277,P37268 7 |
| Cholesterol metabolism with bloch and kandutschrussell pathways 0.6150943104344735 1.0157889513183689 0.3097298985047823 1.0 1.0 25 Q15392,P14324,O75845,O95864,Q16850,Q15125,Q14739,Q15800,Q14534,P35610,O00767,P37268 12 |
| Nuclear receptors in lipid metabolism and toxicity 0.8780487804878194 1.003365113124862 0.3156847302091026 1.0 1.0 2 P08183 1 |
| Cholesterol biosynthesis pathway 0.5794356454585422 0.9914499737969664 0.3214659084903513 1.0 1.0 14 P14324,Q16850,O75845,Q15800,Q14534,P37268 6 |
| Camkk2 pathway 0.5686379344625974 0.9750029441051582 0.3295587995763038 1.0 1.0 12 O76024,P09601,P42345 3 |
| Vitamin b12 disorders 0.6791704788045095 0.962639537436823 0.3357284488504179 1.0 1.0 3 Q99707,P22033 2 |
| Hair follicle development cytodifferentiation part 3 of 3 0.5983594366004907 0.959567021809576 0.33727317324478 1.0 1.0 4 Q04721 1 |
| Ccl18 signaling pathway 0.5512491051119812 0.9499649701895484 0.3421300521943116 1.0 1.0 9 Q86UE4,P08670 2 |
| Preimplantation embryo 0.5351595265377505 0.9377499927463088 0.3483729055990929 1.0 1.0 6 Q99729,Q92945 2 |
| Influence of laminopathies on wnt signaling 0.5523158500214619 0.9343208998701978 0.3501383865856722 1.0 1.0 10 O75844,O60725 2 |
| Rala downstream regulated genes 0.5914122656451987 0.9293922430392626 0.352685846325206 1.0 1.0 4 P11233 1 |
| Omega9 fatty acid synthesis 0.5331448647229122 0.9278958687122004 0.3534615876258313 1.0 1.0 6 O00767 1 |
| Gastric cancer network 2 0.5687742719221918 0.9209557533069236 0.3570735283291124 1.0 1.0 15 Q6PL18,Q86UE4,Q658Y4,Q9HB71,Q03252,Q14739 6 |
| Mitochondrial immune response to sarscov2 0.5402143150590532 0.8958774532155506 0.3703182172836921 1.0 1.0 9 Q99623,Q86UT6,Q9Y6M9,Q9BQ95,Q7Z434,O94826 6 |
| 1q211 copy number variation syndrome 0.5269834037655629 0.8314298298289989 0.4057308534295989 1.0 1.0 9 Q9NPH0 1 |
| Sarscov2 and covid19 pathway 0.5393687517397361 0.7081723210868955 0.4788382525225796 1.0 1.0 4 Q8WTV0 1 |
| Inhibition of exosome biogenesis and secretion by manumycin a in crpc cells 0.4920438349603633 0.7070128354097527 0.4795585013853265 1.0 1.0 7 P31943 1 |
| Urea cycle and related diseases 0.7905487804878372 0.701158451922917 0.4832041355232137 1.0 1.0 2 Q9Y619 1 |
| Electron transport chain oxphos system in mitochondria 0.5679290100419991 0.6916056283136849 0.4891850261596187 1.0 1.0 48 P14406,P06576,P03886,P00403,P13073,O14949,O75964,P12235,Q9Y6M9,O43676,O96000,P56385,O95169,P24539,P22695,Q9UDW1 16 |
| Progeriaassociated lipodystrophy 0.4943079365672431 0.6750427096378026 0.4996486304338927 1.0 1.0 9 O75844 1 |
| Constitutive androstane receptor pathway 0.5045263935368305 0.6691480986550514 0.5034010103320203 1.0 1.0 5 P07900,P08183 2 |
| Arrhythmogenic right ventricular cardiomyopathy 0.5131524841719167 0.6680547460663707 0.5040986471944429 1.0 1.0 14 P12814,P05556,P35222,P16615,P19022,P50402,O43707 7 |
| Adipogenesis 0.5096048107825032 0.6171468413113637 0.53713787495241 1.0 1.0 16 O75844,P43490,P14174 3 |
| Hostpathogen interaction of human coronaviruses autophagy 0.5877171824986555 0.615055144448212 0.5385183034415504 1.0 1.0 3 P42345 1 |
| Osx and mirnas in tooth development 0.7518292682926827 0.5767402357822878 0.5641149475195932 1.0 1.0 2 Q04721 1 |
| Aryl hydrocarbon receptor pathway wp2873 0.501712963530801 0.5564388108030099 0.5779109134163236 1.0 1.0 4 Q16543 1 |
| Overlap between signal transduction pathways contributing to lmna laminopathies 0.4793704595874095 0.5118008759930626 0.6087903772155792 1.0 1.0 14 P11802,O75844,P42167,P50402,O60725 5 |
| Vitamin d receptor pathway 0.457405470277784 0.4497431763335984 0.6528956349877895 1.0 1.0 12 P20020,P08183,Q92604,P09493,P24941,Q96KA5 6 |
| Nephrogenesis 0.7048780487804877 0.437550611037444 0.6617120802146967 1.0 1.0 2 Q04721 1 |
| Mitochondrial complex i assembly model oxphos system 0.5024797287619674 0.4191596038161511 0.6750994926977665 1.0 1.0 29 P03886,P03915,Q96CU9,O75306,Q9Y6M9,Q9BUB7,Q9NPL8,O43676,O96000,O95169,Q9P0J0,Q8IUX1,O95168,O43674 14 |
| Metapathway biotransformation phase i and ii 0.475369508714163 0.4021846820320647 0.6875481146139553 1.0 1.0 20 Q86UY6,Q8NCH0,P21964,Q6UW02,Q7LGA3,P07099 6 |
| Eicosanoid metabolism via cyclooxygenases cox 0.4132378958529662 0.3765898384327414 0.7064784405040323 1.0 1.0 6 O15254 1 |
| 7oxoc and 7betahc pathways 0.4257745361393091 0.3706584979226724 0.7108919056120953 1.0 1.0 9 Q9UBM7,Q15125,O15118 3 |
| Ethanol effects on histone modifications 0.4342878281171861 0.3697139314097495 0.7115956504218339 1.0 1.0 11 P05091,P00374,P41440 3 |
| Fluoroacetic acid toxicity 0.4270911726664729 0.3539339743467286 0.7233883650734192 1.0 1.0 5 P51648 1 |
| Interactome of polycomb repressive complex 2 prc2 0.4215463323934703 0.3337859908126389 0.7385410554678602 1.0 1.0 5 Q9Y2W1,Q9NYF8 2 |
| Oxysterols derived from cholesterol 0.4060642779382338 0.3285495584676561 0.7424961796477256 1.0 1.0 7 Q9UBM7,Q15125 2 |
| Development of ureteric collection system 0.4153168531996509 0.3116457496540463 0.7553097613332338 1.0 1.0 5 P05556,P35222 2 |
| Mir124 predicted interactions with cell cycle and differentiation 0.6478658536585364 0.2912247527236213 0.7708794326882138 1.0 1.0 2 Q13131 1 |
| Sarscov2 b117 variant antagonises innate immune activation 0.6399390243902436 0.273207876077047 0.784693425984462 1.0 1.0 2 O94826 1 |
| Allograft rejection 0.4086894166316656 0.2691013301641404 0.7878517068562494 1.0 1.0 11 P08183,P08670,Q9BY49,P01889 4 |
| Cytosine methylation 0.3967776288561004 0.2490924037632411 0.8032893052267909 1.0 1.0 5 P48735 1 |
| Oxidative phosphorylation 0.4666003866498513 0.2476761610003199 0.8043849780405761 1.0 1.0 31 P06576,P03886,Q9Y6M9,O75964,O96000,O95169,P24539,Q15904 8 |
| Glycosylation and related congenital defects 0.3983619750576716 0.231332967036555 0.8170561371902005 1.0 1.0 11 Q9Y5P6,O75352,O75340,Q9H0U3,Q9BV10,Q2TAA5,Q9BT22,Q13724 8 |
| Ppar signaling pathway 0.4250095742103008 0.2274277236479905 0.8200911646818874 1.0 1.0 18 P23786,Q9UKU0,O15254,O00767,Q15067 5 |
| Purinergic signaling 0.4595913388228222 0.2212255825542242 0.8249167907032398 1.0 1.0 3 P04899,P63096 2 |
| Type 2 papillary renal cell carcinoma 0.3793339897187751 0.2122075981244142 0.8319450792847669 1.0 1.0 8 Q92733 1 |
| Genes controlling nephrogenesis 0.3707995342911135 0.199343478642409 0.8419940705564977 1.0 1.0 7 Q04721,P05556,P35222 3 |
| Mrna protein and metabolite inducation pathway by cyclosporin a 0.4464009957924174 0.1909288616947786 0.848581327742798 1.0 1.0 3 P08195 1 |
| Tryptophan metabolism 0.39836055182316 0.1873819711777573 0.8513611571599897 1.0 1.0 14 Q16836,P05091,Q15392,P51648 4 |
| Nephrotic syndrome 0.395528770849492 0.1778608765622708 0.8588322368594379 1.0 1.0 14 Q14108 1 |
| Transcription factors regulate mirnas related to cardiac hypertrophy 0.4083562061604209 0.116882672449262 0.9069530294089524 1.0 1.0 3 Q9P2K5,P31751 2 |
| Envelope proteins and their potential roles in edmd physiopathology 0.3814007403228751 0.1082129366385116 0.9138267832641852 1.0 1.0 16 O94901,Q9BTV4,P42167,Q14739,P50402 5 |
| Signal transduction through il1r 0.3517388651616918 0.1045280703163175 0.9167502933974604 1.0 1.0 4 Q9H0E2,Q15750,Q9BQ95 3 |
| Endoplasmic reticulum stress response in coronavirus infection 0.3406125555305133 0.0932589078045932 0.92569787658229 1.0 1.0 8 Q12972,Q96C90 2 |
| 15q112 copy number variation syndrome 0.3384272728568481 0.0812256228125284 0.9352625227796928 1.0 1.0 4 Q7L576,Q9BSJ2 2 |
| Nonalcoholic fatty liver disease 0.4433724567501151 0.0811198237925138 0.935346660534866 1.0 1.0 49 P14406,P13073,O14949,Q9Y6M9,O96000,O43676,O95169,Q9P0J0,P22695,Q9UDW1 10 |
| Glial cell differentiation 0.5060975609756094 0.0671702128266965 0.9464461982728336 1.0 1.0 2 P26038 1 |
| Fatty acid betaoxidation 0.3785481986187616 0.0479019042481986 0.96179442176418 1.0 1.0 21 O43772,P23786,Q9UKU0,P16219,Q16836 5 |
| Congenital generalized lipodystrophy cgl 0.4728658536585361 0.0432842744183122 0.9654749266701734 1.0 1.0 2 P31751 1 |
| Mecp2 and associated rett syndrome 0.3799089516842833 0.0422018950421983 0.9663377518826752 1.0 1.0 22 P52597,P35637,P31943,Q99640,P67809 5 |
| Steroid biosynthesis 0.4664634146341458 0.0396856098600582 0.9683437743075782 1.0 1.0 2 P51659 1 |
| Mfap5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement 0.3020137507265442 0.0239989881927658 0.9808534157808488 1.0 1.0 5 P19174,Q07157,P12814 3 |
| Robo4 and vegf signaling pathways crosstalk 0.4216463414634141 0.0218460148017584 0.9825707884294128 1.0 1.0 2 O94813 1 |
| Leptininsulin signaling overlap 0.4082317073170727 0.0185451921888889 0.9852039256014512 1.0 1.0 2 O14654 1 |
| Mammary gland development pathway involution stage 4 of 4 0.4082317073170725 0.0185451921888889 0.9852039256014512 1.0 1.0 2 P04637 1 |
| Nonhomologous end joining 0.3168648978347073 0.0178016357869076 0.985797099798224 1.0 1.0 3 P78527,P12956 2 |
| Wnt signaling in kidney disease 0.3594512195121946 0.0117020020576734 0.9906633663163896 1.0 1.0 2 P35222 1 |
| Mammalian disorder of sexual development 0.3365853658536579 0.0103087976745528 0.9917749151770476 1.0 1.0 2 P35222 1 |
| Nipbl role in dna damage cornelia de lange syndrome 0.295516925892041 0.0077966370034316 0.9937792467328984 1.0 1.0 3 Q13185,Q14676 2 |
|
|
